Traditional drugs being developed for vector borne diseases

Image
IANS New Delhi
Last Updated : Nov 25 2016 | 7:58 PM IST

The central government on Friday said that traditional medicines are being developed for prevention and management of vector borne diseases.

Pre-clinical studies for AYUSH PJ7 -- a new drug for dengue -- have been completed, Minister of State for Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) Shripad Yasso Naik said in a written reply to the Lok Sabha.

The minister said that four research councils set up by the Centre are involved in research activities, inter-alia including development and formulation of new drugs.

These research councils are the Central Council for Research in Ayurvedic Sciences (CCRAS), Central Council for Research in Unani Medicine (CCRUM), Central Council for Research in Siddha (CCRS) and Central Council for Research in Homoeopathy (CCRH).

"CCRAS has recently developed AYUSH PJ7 for dengue and AYUSH SL for filarisis. Pre-clinical studies for both the new drugs has been completed," Naik said.

The CCRAS has formulated Ayush 64, a poly herbal, anti-malarial drug, he said and added that it has made deliberations to conduct clinical studies with Indian Council of Medical Research (ICMR) to counter diseases like dengue.

The minister said that CCRUM has made observational studies on the efficacy of some Unani drugs in the vector borne diseases, like malaria, filarisis and Kala Azar which has showed significant therapeutic effects in subsiding different signs and symptoms in these conditions.

"Clinical management studies on dengue, Japanese encephalitis and acute lymphadenitis due to filariasis have already been conducted by CCRH," he added.

--IANS

and/vgu/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 25 2016 | 7:50 PM IST

Next Story